MedWorm

Rates of Maternal and Perinatal Mortality and Vertical Transmission in Pregnancies Complicated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Co-V-2) Infection: A Systematic Review.

Authors: Delgado A, Santos Lira LC, Soligo Takemoto ML, Katz L, Amorim MM
PMID: 32976369 [PubMed - as supplied by publisher] (Source: Obstetrics and Gynecology)

Feed Item Url: 
https://medworm.com/823186792/rates-of-maternal-and-perinatal-mortality-and-vertical-transmission-in-pregnancies-complicated-by-se/

In Reply.

Authors: Huntley BJF, Huntley ES, Di Mascio D, Chen T, Berghella V, Chauhan SP
PMID: 32976370 [PubMed - as supplied by publisher] (Source: Obstetrics and Gynecology)

Feed Item Url: 
https://medworm.com/823186791/in-reply/

In Reply.

Authors: Hollier LM, Jamieson DJ, Caughey AB, Zahn CM
PMID: 32976372 [PubMed - as supplied by publisher] (Source: Obstetrics and Gynecology)

Feed Item Url: 
https://medworm.com/823186789/in-reply/

ACOG Publications: October 2020.

Authors:
PMID: 32976373 [PubMed - as supplied by publisher] (Source: Obstetrics and Gynecology)

Feed Item Url: 
https://medworm.com/823186788/acog-publications-october-2020/

Medication Abortion Up to 70 Days of Gestation: ACOG Practice Bulletin Summary, Number 225.

Authors:
Abstract
Medication abortion, also referred to as medical abortion, is a safe and effective method of providing abortion. Medication abortion involves the use of medicines rather than uterine aspiration to induce an abortion. The U.S. Food and Drug Administration (FDA)-approved medication abortion regimen includes mifepristone and misoprostol. The purpose of this document is to provide updated evidence-based guidance on the provision of medication abortion up to 70 days (or 10 weeks) of gestation. Information about medication abortion after 70 days of gestation is provided in other ACOG publications ().
PMID: 32976374 [PubMed - as supplied by publisher] (Source: Obstetrics and Gynecology)

Feed Item Url: 
https://medworm.com/823186787/medication-abortion-up-to-70-days-of-gestation-acog-practice-bulletin-summary-number-225/

Screening for Fetal Chromosomal Abnormalities: ACOG Practice Bulletin Summary, Number 226.

Authors:
Abstract
Prenatal testing for chromosomal abnormalities is designed to provide an accurate assessment of a patient's risk of carrying a fetus with a chromosomal disorder. A wide variety of prenatal screening and diagnostic tests are available; each offers varying levels of information and performance, and each has relative advantages and limitations. When considering screening test characteristics, no one test is superior in all circumstances, which results in the need for nuanced, patient-centered counseling from the obstetric care professional and complex decision making by the patient. Each patient should be counseled in each pregnancy about options for testing for fetal chromosomal abnormalities. It is important that obstetric care professionals be prepared to discuss...

Feed Item Url: 
https://medworm.com/823186786/screening-for-fetal-chromosomal-abnormalities-acog-practice-bulletin-summary-number-226/

The Initial Reproductive Health Visit: ACOG Committee Opinion Summary, Number 811.

Authors:
Abstract
The primary goal of the initial reproductive health visit is to provide preventive health care services, educational information, and guidance, in addition to problem-focused care. The initial reproductive health visit should take place between the ages of 13 and 15 years. The scope of the initial visit will depend on the patient's concerns, medical history, physical and emotional development, and the level of care the patient is receiving from other health care professionals. All adolescents should have the opportunity to discuss health issues with a health care professional one-on-one, because they may feel uncomfortable talking about these issues in the presence of a parent or guardian, sibling, or intimate partner. Addressing confidentiality concerns is imper...

Feed Item Url: 
https://medworm.com/823186785/the-initial-reproductive-health-visit-acog-committee-opinion-summary-number-811/

Topical Hemostatic Agents at Time of Obstetric and Gynecologic Surgery: ACOG Committee Opinion Summary, Number 812.

Authors:
Abstract
There are three broad categories of hemostatic agents: 1) caustic, 2) physical, and 3) biologic. Because of the paucity of data on the use of topical hemostatic agents in gynecologic and obstetric surgery, indications for use are extrapolated from data on the use of these agents in other types of surgeries and are based on expert opinion. Topical hemostatic agents can be a useful adjunct to assist in the management of intraoperative bleeding in select circumstances. Topical hemostatic agents most commonly are used in situations where the use of electrocautery or sutures for hemostatic control of surgical bleeding is not ideal or safe, including bleeding in areas with nearby vulnerable structures or in the presence of diffuse bleeding from peritoneal surfaces or c...

Feed Item Url: 
https://medworm.com/823186784/topical-hemostatic-agents-at-time-of-obstetric-and-gynecologic-surgery-acog-committee-opinion-summa/

The Initial Reproductive Health Visit: ACOG Committee Opinion, Number 811.

Authors:
Abstract
The primary goal of the initial reproductive health visit is to provide preventive health care services, educational information, and guidance, in addition to problem-focused care. The initial reproductive health visit should take place between the ages of 13 and 15 years. The scope of the initial visit will depend on the patient's concerns, medical history, physical and emotional development, and the level of care the patient is receiving from other health care professionals. All adolescents should have the opportunity to discuss health issues with a health care professional one-on-one, because they may feel uncomfortable talking about these issues in the presence of a parent or guardian, sibling, or intimate partner. Addressing confidentiality concerns is imper...

Feed Item Url: 
https://medworm.com/823186783/the-initial-reproductive-health-visit-acog-committee-opinion-number-811/

Pages